LH response
Rapid after administration, and brief for kisspeptin-10.
Protocol / Research Dosing Guide
Kisspeptin-10 Dosage Guide: Trial Context, Vial Math and Safety
A source-gated Kisspeptin-10 reference that separates published kisspeptin-54 trial protocols from the shorter kisspeptin-10 form sold for research use.
Last reviewed September 16, 202616 minute readResearch information only
Level 3 — Limited human researchTrial data mostly uses kisspeptin-54Not FDA approved
Kisspeptin-10 Quick Start
Kisspeptin-10 is the short form of the kisspeptin signal and acts upstream of GnRH to trigger LH and FSH release. It acts fast and clears fast: after intravenous dosing its blood half-life is roughly four minutes. Most human trial data uses the longer kisspeptin-54 form, and those trial doses are given in nmol/kg, so they do not convert neatly to a microgram amount.
Why researchers care
GnRH pulse generation, LH and FSH response, reproductive-axis research
Class
Decapeptide fragment of kisspeptin acting at the KISS1R (GPR54) receptor
Route reported
Subcutaneous in research-use planning; intravenous in several trials
Cycle length
Short pulse cycles reported because of desensitization
Regulatory status
Not FDA approved
Loading supplier information
Kisspeptin-10 Dosing Protocol and Schedule
The supplied source reports research-context kisspeptin-10 ranges of 50–100 mcg once daily subcutaneously, 100–200 mcg once daily, or 100 mcg twice daily, and separately lists kisspeptin-54 trial protocols in nmol/kg.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Low-dose pulse | 50–100 mcg once daily subcutaneously | Research-context reported |
| Standard pulse | 100–200 mcg once daily subcutaneously | Research-context reported |
| Split dose | 100 mcg twice daily subcutaneously | Research-context reported |
| Short pulse cycle | 2–4 weeks active, 2–4 weeks off | Reported cycle structure |
| Standard cycle | 4–6 weeks active, 4 weeks off | Reported cycle structure |
Continuous exposure can make the LH signal fade, an effect called tachyphylaxis or desensitization. That is why reported structures use short pulses rather than nonstop exposure.
Kisspeptin-10 Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
U-100 insulin syringes, 0.3 mL barrel for accurate small draws
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label
Kisspeptin-10 Reconstitution Calculator
Vial-format concentration math
Concentration
5 mg/mL
Draw volume
0.02 mL
U-100 units
2
Mathematical draws
100
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Kisspeptin-10: Morning or Night?
Time of day?
Not established. Reported low-dose planning often describes administration before sleep.
Once or twice daily?
Both appear in reported research-context ranges.
Continuous use?
Avoided in reported practice because the LH response fades with sustained exposure.
Missed amount?
No validated procedure exists.
Kisspeptin-10 Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Subcutaneous kisspeptin-10 | The form most research-use suppliers stock | Short signal window |
| Subcutaneous kisspeptin-54 | Used in IVF trigger and desire-related trials | Different molecule and duration |
| Intravenous infusion | Used in several published trials | Not a research-community route |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Kisspeptin-10 Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Kisspeptin-10 (intravenous) | About 4 minutes | Published |
| Kisspeptin-54 (subcutaneous) | About 28 minutes, with LH elevated for several hours | Published |
| Why pulses are short | The LH and FSH signal is brief even when a subcutaneous route stretches it slightly | Reported rationale |
| Desensitization | Sustained exposure reduces the response over time | Observed in a chronic twice-weekly trial |
Kisspeptin-10 Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous (K-10) | 50–100 mcg | Once daily | Research-context report | No |
| Subcutaneous (K-10) | 100–200 mcg | Once daily | Research-context report | No |
| Subcutaneous (K-10) | 100 mcg | Twice daily | Research-context report | No |
| Subcutaneous (K-54) | 1.6–12.8 nmol/kg single bolus | IVF trigger studies | Clinical trial | No |
| Subcutaneous (K-54) | 6.4 nmol/kg | Twice weekly | Hypothalamic amenorrhea trial | No |
| Intravenous (K-54) | 1 nmol/kg/hour | 75-minute infusion | Clinical trial | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Kisspeptin-10 Reconstitution Guide
Concentration: 5 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 0.1 mg | 0.02 mL | 2 units |
| 0.2 mg | 0.04 mL | 4 units |
| 0.3 mg | 0.06 mL | 6 units |
- 1.Confirm the milligram total on the vial label.
- 2.Record the exact bacteriostatic water volume added.
- 3.Clean the stopper with an alcohol swab.
- 4.Add liquid slowly down the vial wall.
- 5.Swirl gently until clear; do not shake.
- 6.A 10 mg vial with 2 mL gives 5 mg/mL, so 100 mcg is 0.02 mL, which is 2 units on a U-100 syringe.
- 7.If the vial size or water volume differs, redo the arithmetic before drawing.
- 8.Label the concentration and preparation date, then refrigerate.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Kisspeptin-10 Works
Receptor target
Kisspeptin binds KISS1R, also called GPR54, on GnRH neurons.
Kisspeptin-10 Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved
- Kisspeptin-54 has been studied as an IVF oocyte-maturation trigger in phase 2 work, including a 60-woman trial at Hammersmith Hospital and a 53-woman proof-of-concept trial where LH peaked at about five hours.
- A chronic twice-weekly subcutaneous trial in hypothalamic amenorrhea reported a reduced response over time consistent with desensitization.
- Imperial College and Hammersmith infusion trials between 2021 and 2023 examined kisspeptin in desire-related endpoints in women and men.
- Kisspeptin-10 itself is not FDA approved and has no established therapeutic dose.
Who Should Avoid Kisspeptin-10?
This is an evidence-gap and precaution list, not an approved prescribing label.
Pregnancy or breastfeeding
No safety data outside supervised trials
Hormone-sensitive conditions
Reproductive-axis stimulation is not evaluated in this setting
Children or adolescents
Puberty-axis effects are not characterized
Undiagnosed endocrine or fertility problems
Requires clinical diagnosis before any hormone intervention
Continuous unsupervised use
Desensitization and unmonitored hormone change
Kisspeptin-10 Side Effects, Risks and Safety
Injection-site reactionAnecdotal
Important limitation: No controlled incidence data.
Flushing or nauseaReported in trial settings
Important limitation: Generally transient.
HeadacheAnecdotal
Important limitation: No controlled incidence data.
Hormone-axis disruptionMechanistic
Important limitation: Sustained exposure reduces response.
Drug interactionsUnknown
Important limitation: No interaction studies for research-use protocols.
Long-term effectsUnknown
Important limitation: No follow-up evidence.
Kisspeptin-10 Timeline and Monitoring
Kisspeptin-54 trial window
LH peaked at about five hours and returned to pre-trigger levels by 12 to 14 hours.
Reported cycles
Two to six weeks active with a matching off period.
Monitoring
No validated monitoring schedule exists outside trials.
Kisspeptin-10 Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| LH and FSH release | Demonstrated in human studies | Level 3 | Acute signal, not an outcome |
| IVF trigger use | Trial evidence with kisspeptin-54 | Level 3 | Different molecule |
| Testosterone increase | Conditional | Depends on testicular responsiveness | Not a validated protocol |
| Desire-related endpoints | Trial research with kisspeptin-54 | Level 3 | Not transferable to kisspeptin-10 |
Kisspeptin-10 Storage and Handling
Unreconstituted vial
Follow the product label; keep cool, dry and out of light.
Prepared vial
Refrigerate and protect from light.
Freezing
Repeated freeze-thaw cycles are avoided for peptide solutions.
Appearance
Cloudiness, discoloration or particles mean the solution should not be used.
Kisspeptin-10 Troubleshooting
nmol/kg values will not convert
They depend on body weight. For example, 6.4 nmol/kg of kisspeptin-54 is about 2.85 mg for a 70 kg subject.
Response seems to fade
That pattern matches reported desensitization from sustained exposure.
Units look too small
At 5 mg/mL, 100 mcg is only 2 units; use a 0.3 mL syringe for a readable draw.
Solution appears cloudy
Stop and seek qualified product guidance.
Unexpected symptoms
Seek licensed clinical review.
Kisspeptin-10 Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Kisspeptin-10 | Short decapeptide form | About 4 minute intravenous half-life | Not approved |
| Kisspeptin-54 | Full-length form used in trials | About 28 minute subcutaneous half-life | Not approved |
| HCG | Acts directly at the LH receptor | Downstream of kisspeptin | Approved in defined indications |
Kisspeptin-10 Frequently Asked Questions
What is kisspeptin-10?
A decapeptide that acts at KISS1R on GnRH neurons to trigger LH and FSH release.
Is it FDA approved?
No.
What is its half-life?
About four minutes after intravenous dosing.
Why do trials use kisspeptin-54?
It lasts longer, with about a 28 minute subcutaneous half-life and hours of raised LH.
Can nmol/kg trial doses be converted to mcg?
Not neatly. The conversion depends on body weight and on which form is used.
What is tachyphylaxis here?
The fading LH response seen with continuous exposure.
What does a 10 mg vial with 2 mL give?
5 mg/mL, so 100 mcg is 2 units on a U-100 syringe.
Does it raise testosterone?
Human data shows LH can rise; a testosterone rise depends on the testes responding.
Is a cycle length validated?
No. Reported two-to-six week structures are research-context planning, not trial protocols.
How long does a 10 mg vial last?
At 100 mcg per administration it covers roughly 100 planned draws before losses.
What does the calculator do?
Concentration and volume arithmetic only.
Sources and Research
Coverage source
1. Kisspeptin protocol coverage source
Supplied coverage source for research-context ranges, cycle structures and vial arithmetic.
Open direct sourceClinical trial
2. Kisspeptin-54 as an oocyte maturation trigger in IVF
Phase 2 trial work reporting nmol/kg bolus dosing and LH response windows.
Open direct sourcePublished research
3. Kisspeptin and the GnRH pulse generator
Published physiology of KISS1R signalling and LH release, including desensitization.
Open direct sourceMissing information flagged for review
- Validated kisspeptin-10 human dose: Not established
- Subcutaneous kisspeptin-10 pharmacokinetics: Not established
- Validated cycle and rest period: Not established
- Long-term safety data: Not established
- Kisspeptin-10 to kisspeptin-54 equivalence: Not established